Results 1 – 10 of 240 for copd foundation (0.04 seconds)

Real world study comparing commonly prescribed COPD medicines shows choice of treatment has impact on patient outcomes

Real world study comparing commonly prescribed COPD medicines shows choice of treatment has impact on patient outcomes

Benralizumab Phase II COPD study published in The Lancet Respiratory Medicine

Benralizumab Phase II COPD study published in The Lancet Respiratory Medicine

AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of Breztri to improve cardiopulmonary outcomes in people with COPD

to improve cardiopulmonary outcomes in people with COPD

Bevespi Aerosphere approved in China for patients with COPD

Bevespi Aerosphere approved in China for patients with COPD

Trixeo Aerosphere approved in the EU for maintenance treatment of COPD

Trixeo Aerosphere approved in the EU for maintenance treatment of COPD

Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in Phase III ETHOS trial

Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in Phase III ETHOS trial

New analyses from Breztri Aerosphere Phase III ETHOS trial to be presented at the European Respiratory Society International Congress 2020

Breztri Aerosphere reduced rate of COPD exacerbations across all seasons  compared with Bevespi Aerosphere AstraZeneca to present 60 abstracts ...

Trixeo Aerosphere recommended for approval in the EU by CHMP for the maintenance treatment of COPD

Trixeo Aerosphere recommended for approval in the EU by CHMP for the maintenance treatment of COPD

AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD

AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD

Bevespi Aerosphere approved in the EU for chronic obstructive pulmonary disease

patients with chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere is the first medicine in its class to be approved by the EC in a pMDI. ...

Previous 1 2 3 4 5 6 7 8 9 10 Next